Small-Molecule Oral Versus Injectable Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Comparative Efficacy, Safety, and Future Clinical Perspectives

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the management of type 2 diabetes (T2D), obesity, and cardiometabolic disease by improving glycemic control, promoting clinically meaningful weight loss, and reducing major adverse cardiovascular events (MACE) in selected populations. Historically, GLP-1RA therapy has relied on injectable peptide agonists (e.g., liraglutide, semaglutide, dulaglutide, and exenatide), which mimic native incretin biology but require parenteral administration and cold-chain logistics. In parallel, oral GLP-1RAs have emerged through two distinct strategies: (1) the oral delivery of peptide agonists using absorption enhancers (e.g., oral semaglutide) and (2) true small-molecule, non-peptide GLP-1 receptor agonists (e.g., orforglipron), designed to be orally bioavailable without peptide constraints. This narrative review compares small-molecule oral GLP-1RAs to injectable peptide agonists across efficacy (glycated hemoglobin {HbA1c} lowering, weight reduction, and cardiometabolic outcomes), safety and tolerability (gastrointestinal {GI} adverse events, gallbladder disease, pancreatitis signals, retinopathy considerations, and rare hepatic signals), real-world adherence, and future innovation. Recent phase 3 evidence suggests that oral small-molecule GLP-1RAs can deliver glycemic and weight benefits approaching injectable standards, while high-dose oral peptide formulations may broaden oral options for obesity management. Remaining challenges include long-term outcome data, the optimization of titration to improve tolerability, and equitable access amid rapid market expansion.